{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:02:30Z","timestamp":1790197350986,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T00:00:00Z","timestamp":1517529600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1038\/s41375-018-0013-4","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T13:04:27Z","timestamp":1517576667000},"page":"1427-1434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression"],"prefix":"10.1038","volume":"32","author":[{"given":"Carlos","family":"Fern\u00e1ndez de Larrea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Isola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma Teresa","family":"Cibeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Magnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Tovar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis-Gerardo","family":"Rodr\u00edguez-Lobato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan I.","family":"Ar\u00f3stegui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Rozman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Yag\u00fce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,2]]},"reference":[{"key":"13_CR1","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/leu.2010.60","volume":"24","author":"RA Kyle","year":"2010","unstructured":"Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24:1121\u201327.","journal-title":"Leukemia"},{"key":"13_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.100","volume":"6","author":"A Ravindran","year":"2016","unstructured":"Ravindran A, Bartley AC, Holton SJ, Gonsalves WI, Kapoor P, Siddiqui MA, et al. Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Blood Cancer J. 2016;6:e486.","journal-title":"Blood Cancer J"},{"key":"13_CR3","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"International Myeloma Working Group.","year":"2003","unstructured":"International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749\u201357.","journal-title":"Br J Haematol"},{"key":"13_CR4","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1200\/JCO.2009.22.2257","volume":"28","author":"J Blad\u00e9","year":"2010","unstructured":"Blad\u00e9 J, Dimopoulos M, Rosi\u00f1ol L, Rajkumar SV, Kyle RA. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol. 2010;28:690\u201397.","journal-title":"J Clin Oncol"},{"key":"13_CR5","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin P, Hodnefield J, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356:2582\u201390.","journal-title":"N Engl J Med"},{"key":"13_CR6","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","volume":"111","author":"A Dispenzieri","year":"2008","unstructured":"Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111:785\u201389.","journal-title":"Blood"},{"key":"13_CR7","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","volume":"110","author":"E P\u00e9rez-Persona","year":"2007","unstructured":"P\u00e9rez-Persona E, Vidriales MB, Mateo G, Garc\u00eda-Sanz R, Mateos MV, de Coca AG, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110:2586\u201392.","journal-title":"Blood"},{"key":"13_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1365-2141.2009.07929.x","volume":"148","author":"E P\u00e9rez-Persona","year":"2010","unstructured":"P\u00e9rez-Persona E, Mateo G, Garc\u00eda-Sanz R, Mateos MV, de Las Heras N, de Coca AG, et al. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of the monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol. 2010;148:110\u201314.","journal-title":"Br J Haematol"},{"key":"13_CR9","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.3109\/10428194.2013.764419","volume":"54","author":"BM Cherry","year":"2013","unstructured":"Cherry BM, Korde N, Kwok M, Manasanch EE, Bhutani M, Mulquin M, et al. Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk Lymphoma. 2013;54:2215\u201318.","journal-title":"Leuk Lymphoma"},{"key":"13_CR10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1046\/j.1365-2141.2003.04654.x","volume":"123","author":"L Rosi\u00f1ol","year":"2003","unstructured":"Rosi\u00f1ol L, Blad\u00e9 J, Esteve J, Aymerich M, Rozman M, Montoto S, et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol. 2003;123:631\u201336.","journal-title":"Br J Haematol"},{"key":"13_CR11","doi-asserted-by":"publisher","first-page":"428","DOI":"10.4065\/82.4.428","volume":"82","author":"L Rosi\u00f1ol","year":"2007","unstructured":"Rosi\u00f1ol L, Cibeira MT, Montoto S, Rozman M, Esteve J, Filella X, et al. Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size. Mayo Clin Proc. 2007;82:428\u201334.","journal-title":"Mayo Clin Proc"},{"key":"13_CR12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","volume":"81","author":"PM Grambsch","year":"1994","unstructured":"Grambsch PM, Therneau TM. Proportional Hazards Tests and Diagnostics based on Weighted Residuals. Biometrika. 1994;81:515\u201326.","journal-title":"Biometrika"},{"key":"13_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/mpr.124","volume":"11","author":"LR Schultz","year":"2002","unstructured":"Schultz LR, Peterson EL, Breslau N. Graphing survival curve estimates for time-dependent covariates. Int J Methods Psychiatr Res. 2002;11:68\u201374.","journal-title":"Int J Methods Psychiatr Res"},{"key":"13_CR14","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","volume":"302","author":"RA Kyle","year":"1980","unstructured":"Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med. 1980;302:1347\u201349.","journal-title":"N Engl J Med"},{"key":"13_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/j.1365-2141.2005.05673.x","volume":"130","author":"L Rosi\u00f1ol","year":"2005","unstructured":"Rosi\u00f1ol L, Carri\u00f3 A, Blad\u00e9 J, Queralt R, Aymerich M, Cibeira MT, et al. Comparative genomic hybridization identifies two variants of smoldering multiple myeloma. Br J Haematol. 2005;130:729\u201332.","journal-title":"Br J Haematol"},{"key":"13_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.65","volume":"6","author":"P Ravi","year":"2016","unstructured":"Ravi P, Kumar S, Larsen JT, Gonsalves W, Buadi F, Lacy MQ, et al. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J. 2016;6:e454.","journal-title":"Blood Cancer J"},{"key":"13_CR17","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564\u201369.","journal-title":"N Engl J Med"},{"key":"13_CR18","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","volume":"125","author":"SV Rajkumar","year":"2015","unstructured":"Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood. 2015;125:3069\u201375.","journal-title":"Blood"},{"key":"13_CR19","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1300439","volume":"369","author":"MV Mateos","year":"2013","unstructured":"Mateos MV, Hern\u00e1ndez MT, Giraldo P, de la Rubia J, de Arriba F, L\u00f3pez Corral L, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369:438\u201347.","journal-title":"N Engl J Med"},{"key":"13_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1634\/theoncologist.2015-0303","volume":"21","author":"J Caers","year":"2016","unstructured":"Caers J, Fern\u00e1ndez de Larrea C, Leleu X, Heusschen R, Zojer N, Decaux O, et al. The Changing landscape of smoldering multiple myeloma: a European perspective. Oncologist. 2016;21:333\u201342.","journal-title":"Oncologist"},{"key":"13_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","volume":"123","author":"MV Dhodapkar","year":"2014","unstructured":"Dhodapkar MV, Sexton R, Waheed S, Usmani S, Papanikolaou X, Nair B, et al. Clinical, genomic, and imaging predictors of mieloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood. 2014;123:78\u201385.","journal-title":"Blood"},{"key":"13_CR22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/leu.2016.205","volume":"31","author":"WI Gonsalves","year":"2016","unstructured":"Gonsalves WI, Rajkumar SV, Dispenzieri A, Dingli D, Timm MM, Morice WG, et al. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia. 2016;31:130\u201335.","journal-title":"Leukemia"},{"key":"13_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/leu.2012.201","volume":"27","author":"JA Katzmann","year":"2013","unstructured":"Katzmann JA, Rajkumar SV. A window into immunoglobulin quantitation and plasma cell disease: antigen epitopes defined by the junction of immunoglobulin heavy and light chains. Leukemia. 2013;27:1\u20132.","journal-title":"Leukemia"},{"key":"13_CR24","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/j.clml.2016.02.034","volume":"16","author":"L Magnano","year":"2016","unstructured":"Magnano L, Fern\u00e1ndez de Larrea C, Elena M, Cibeira MT, Tovar N, Ar\u00f3stegui JI, Pedrosa F, et al. Prognostic impact of serum heavy\/light chain pairs in patients with monoclonal gammopathy of undetermined significance and smoldering myeloma: long-term results from a single institution. Clin Lymphoma Myeloma Leuk. 2016;16:e71\u20137.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"13_CR25","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.","journal-title":"Lancet Oncol"},{"key":"13_CR26","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1056\/NEJMc1106428","volume":"365","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med. 2011;365:474\u201375.","journal-title":"N Engl J Med"},{"key":"13_CR27","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/leu.2012.296","volume":"27","author":"JT Larsen","year":"2013","unstructured":"Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia. 2013;27:941\u201346.","journal-title":"Leukemia"},{"key":"13_CR28","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","volume":"28","author":"J Hillengass","year":"2010","unstructured":"Hillengass J, Fechtner K, Weber MA, B\u00e4uerle T, Ayyaz S, Heiss C, et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol. 2010;28:1606\u201310.","journal-title":"J Clin Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0013-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0013-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0013-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:32:42Z","timestamp":1684618362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-018-0013-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,2]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["13"],"URL":"https:\/\/doi.org\/10.1038\/s41375-018-0013-4","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,2]]},"assertion":[{"value":"26 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}